

Rec'd PCT/PTO 22 DEC 2005

Attorney Docket No.: 105202/US/2  
Attorney File No. 435689-00014**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention

**TCF/B-Catenin Regulated Genes For Treating Cancer**

As the below named inventors, we declare that:

This declaration is directed to:

International Application No. PCT/EP03/07399 filed on July 8, 2005.

We believe that we are the original and first inventors of the subject matter which is claimed and for which a patent is sought;

We have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

We acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.



All statements made herein of our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

**FULL NAME OF INVENTORS**Inventor one: Frederic CollandSignature: [Signature] Citizen of: FrancoInventor two: Nicholas BarkerSignature: [Signature] Citizen of: The NetherlandsInventor three: Johannes Carolus CloversSignature: [Signature] Citizen of: The NetherlandsInventor four: Eduard GomezSignature: [Signature] Citizen of: Spain

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is intended to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No: 186208/US2  
Attorney File No: 455669-00014

500  
600

Inventor five:	Marcus Lambertus Van Do Wetering
Signature:	 Citizen of: The Netherlands
Inventor six:	Elena Sancho Sullis
Signature:	 Citizen of: Spain

**POWER OF ATTORNEY BY ASSIGNEE**


The undersigned assignee of the entire interest in application for letters patent entitled: **TCF/B-Catenin Regulated Genes For Treating Cancer** and having the named inventor(s), **Frederic Colland, Nicholas Barker, Johannes Carolus Clevers, Eduard Gomez, Marcus Lambertus Van De Wetering And Elena Sancho Suils** filed **July 8, 2005** as Serial No. **PCT/EP03/07399**, hereby appoints the Dorsey & Whitney LLP attorneys and agents associated with **Customer Number 32940** to prosecute the patent application identified above and to transact all business in the Patent and Trademark Office connected therewith, including full power of association, substitution, and revocation, said appointment to be to the exclusion of the inventor(s) and his (their) attorney(s) in accordance with the provisions of 37 C.F.R. 1.32; provided that if any one of said attorneys ceases being affiliated with the law firm of DORSEY & WHITNEY LLP as partner, employee or of counsel, such attorney's appointment as attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

In accordance with 37 CFR 3.73 the assignee hereby certifies that the evidentiary documents with respect to its ownership have been reviewed and that, to the best of assignee's knowledge and belief, title is in the assignee seeking to take this action.

Direct all telephone calls to Richard F. Trecartin, Esq. at (415) 781-1989.

Address all correspondence to:

Richard F. Trecartin, Esq.  
DORSEY & WHITNEY LLP  
Four Embarcadero Center, Suite 3400  
San Francisco, CA 94111-4187

Assignee	<u>Kylis B. V. Corporation</u>
Name & Title	<u>J. P. de Koning / Managing Director</u> Buntlaan 44 Driebergen, The Netherlands 3971 JD
Address	<u>JD</u>
	<u></u> Signature

Date 14 Oct 2005

File No. 186208/US/2  
455569-00014